PacBio

262 articles about PacBio

• PacBio Announces Collaboration with Leading Library Preparation Automation Partners

  9/7/2023

  PacBio today announced that automation providers Hamilton, Integra, Revvity and Tecan have created fully automated protocols to prepare samples for sequencing on Revio and Sequel II and IIe systems.

• PacBio to Present at Upcoming Investor Conferences - August 09, 2023

  8/9/2023

  PacBio, a leading developer of high-quality, highly accurate sequencing solutions, announced that management will be participating in the following upcoming investor conferences:

• PacBio and GeneDx Launch Research Collaboration with the University of Washington to Study Long-Read Whole Genome Sequencing for Increased Diagnostic Yield in Neonatal Care

  8/7/2023

  PacBio and GeneDx today announced a research collaboration with the University of Washington to study the capabilities of HiFi long-read whole genome sequencing (WGS) to increase diagnostic rates in pediatric patients with genetic conditions.

• PacBio Reports Equity Incentive Awards to New Employees Under Nasdaq Listing Rule 5635(c)(4)

  8/5/2023

  PacBio announced that PacBio's Compensation Committee of the Board of Directors granted non-qualified stock options covering an aggregate of 100,000 shares of PacBio common stock and restricted stock units covering 184,700 shares of PacBio common stock to fourteen non-executive employees.

• PacBio Announces Second Quarter 2023 Financial Results

  8/2/2023

  PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2023.

• PacBio Begins Commercialization of the Onso Short-Read Sequencing System

  8/2/2023

  PacBio, a leading developer of high-quality, highly accurate sequencing solutions, announced that customer shipments of Onso short-read sequencing instruments will commence.

• PacBio to Report Second Quarter 2023 Financial Results on August 2, 2023

  7/19/2023

  PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its second quarter 2023 financial results on Wednesday, August 2, 2023, at 5:00 pm Eastern Time.

• Sampled Named a Certified Service Provider for PacBio

  7/11/2023

  Sampled today announced that it has been named a Certified Service Provider for PacBio, a leading developer of high-quality, highly accurate sequencing solutions, equipping Sampled to deliver the highest quality advanced sequencing technology services on PacBio’s technology.

• PacBio's Revio System Empowers Bioscientia to Scale Long-Read Whole Genome Sequencing and Unravel the Mysteries of Rare Disease

  6/28/2023

  PacBio today announced that Bioscientia  is using its Revio long-read sequencing systems to expand its genomics research projects and sequence several thousand human genomes per year.

• PacBio Announces a Private Convertible Exchange Transaction of $441 Million Principal Amount of 1.375% Convertible Senior Notes due 2030

  6/26/2023

  PacBio announced that it has entered into a privately negotiated exchange agreement with a holder of PacBio's outstanding 1.50% Convertible Senior Notes due 2028, pursuant to which PacBio will issue $441 million principal amount of its 1.375% Convertible Senior Notes due 2030 in exchange for $441 million principal amount of the 2028 Notes, in a transaction exempt from registration under the Securities Act of 1933, as amended, and the rules and regulations thereunder.

• PacBio and Radboud University Medical Center Team Up for New Discoveries in Rare Disease Research

  6/14/2023

  PacBio, a leading developer of high-quality, highly accurate sequencing solutions announced a clinical research study with Radboud University Medical Center to explore genetic causes of rare and genetic diseases.

• PacBio Announces the Appointment of Olga Troyanskaya from Princeton University to the Scientific Advisory Board

  5/30/2023

  PacBio announced the appointment of Olga Troyanskaya, Ph.D., Professor of Computer Science and the Lewis Sigler Institute for Integrative Genomics at Princeton University to PacBio's Scientific Advisory Board and Jay Shendure, Ph.D. as Chair.

• PacBio to Present at Upcoming June 2023 Investor Conferences

  5/25/2023

  PacBio, a leading developer of high-quality, highly accurate sequencing solutions, announced that it will be participating in the following upcoming investor conferences.

• PacBio to Present at BofA Securities 2023 Health Care Conference

  5/3/2023

  PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that it will be participating in the BofA Securities 2023 Health Care Conference in Las Vegas, Nevada.

• PacBio Announces Record Revenue in First Quarter 2023

  5/2/2023

  PacBio announced financial results for the quarter ended March 31, 2023.

• PacBio to Report First Quarter 2023 Financial Results on May 2, 2023

  4/18/2023

  PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its first quarter 2023 financial results on Tuesday, May 2, 2023, at 4:30 pm Eastern Time.

• PacBio Announces New Nanobind Extraction Kits to Enable High-Throughput Workflows with Revio and Sequel Systems

  4/5/2023

  PacBio, a leading developer of high-quality, highly accurate sequencing solutions, announced the availability of its new high-throughput Nanobind DNA Extraction kits, another key product from the highly valuable Circulomics acquisition.

• PacBio and Corteva Agriscience Enable Groundbreaking Plant and Microbial Long-Read Sequencing Workflow on Revio System

  3/28/2023

  PacBio, a leading developer of high-quality, highly accurate sequencing solutions, announced new workflows developed with global agriculture company, Corteva Agriscience that enable high throughput plant and microbial genome sequencing.

• PacBio Announces a New Informatics Analysis Method for Highly Homologous Genes

  3/14/2023

  PacBio, a leading developer of highly accurate sequencing solutions, announced a new informatics method that genotypes gene paralogs and pseudogenes with high accuracy.

• PacBio To Begin Commercial Shipment of Revio Systems

  3/7/2023

  PacBio, a leading developer of high-quality, highly accurate sequencing solutions, announced the first customer shipments of Revio long-read sequencing systems will commence on March 8, 2023.